U-47700

U-47700
Chemical Nomenclature
Common names	U-47700
Systematic name	trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide
Class Membership
Psychoactive class	Opioid
Chemical class	Benzamide
Routes of Administration
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section. ⇣ Insufflated Dosage Threshold 1 mg Light 4 - 6 mg Common 6 - 8 mg Strong 8 - 10 mg Heavy 10 mg + Duration Total 2 - 3 hours Onset 5 - 10 minutes Come up 15 - 20 minutes Peak 1 - 2 hours After effects 2 - 4 hours DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
Interactions
Stimulants
MAOIs
Nitrous
PCP
Alcohol
Benzodiazepines
DXM
GHB
GBL
Ketamine
MXE
Tramadol
Grapefruit

Summary sheet: U-47700

U-47700 is an opioid within the benzamide chemical class. It has very little history of human usage and is currently available through the use of certain online research chemical vendors.

This compound was initially developed by a team at Upjohn in the 1970s. Upjohn created over a dozen patents on related compounds until they discovered that U-47700 was the most active. This was done by looking for the key functional groups which gave the greatest activity.

Chemistry

This chemistry section is incomplete. You can help by adding to it.

U-47700 is an atypical opioid of the benzamide class. It features core benzene ring, with two chlorine atoms at carbons R₃ and R₄ as well as an amide group attached to it. The terminal nitrogen atom of the amide group features a methyl substitution and a N,N-dimethylcyclohexanamine ring.

Pharmacology

U-47700 is selective for the µ-opioid receptor, with various sources claiming 7.5x the potency of morphine.

Opioids exert their effects by binding to and activating the μ-opioid receptor. This occurs because opioids structurally mimic endogenous endorphins which are naturally found within the body and also work upon the μ-opioid receptor set. The way in which opioids structurally mimic these natural endorphins results in their euphoria, pain relief and anxiolytic effects. This is because endorphins are responsible for reducing pain, causing sleepiness, and feelings of pleasure. They can be released in response to pain, strenuous exercise, orgasm, or general excitement.

U-47700 may also be an agonist for the kappa-opioid receptor system. As a result of this, it has become the lead compound of selective kappa-opioid receptor ligands such as U-50488 and U-69,593, which share very similar structures. Its structure led to other chemists experimenting with it to see if rigid analogues would retain activity. Although not used medically, the selective kappa ligands are used in research.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

Physical effects

The general head space of U-47700 is described by many as one of euphoria, relaxation, anxiety suppression and pain relief. Its effects are considered to be similar to oxycodone by several members of Bluelight.

• Pain relief
• Physical euphoria - This particular substance is considered to cause less physically intense euphoria as compared to morphine or diacetylmorphine (heroin). This sensation is described as moderate feelings of physical comfort, warmth and physical euphoria which spreads throughout the body.
• Itchiness - This compound, like most opioids, tends to cause strong histamine reactions which cause the skin to feel itchy.
• Respiratory depression - Although it has not been formally studied, anecdotal reports suggest that respiratory depression is significantly stronger with this compound in comparison to other more common opioids such as heroin and morphine at relative doses. At low to moderate doses, this effect results in the sensation that the breath is slowed down mildly to moderately, but does not cause noticeable impairment. At high doses and overdoses, opioid-induced respiratory depression can result in a shortness of breath, abnormal breathing patterns, semi-consciousness, or unconsciousness. Severe overdoses can result in a coma or death without immediate medical attention.
• Sedation - With high dosages, this compound causes considerably stronger sedation than oxycodone or hydrocodone.
• Constipation
• Cough suppression
• Difficulty urinating
• Pupil constriction
• Decreased libido

Cognitive effects

• Cognitive euphoria - This particular substance can be considered as less intense in its cognitive euphoria when compared with that of morphine or diacetylmorphine (heroin) due to its short duration and structural differences. It is still, however, capable of extreme intensity and overwhelming bliss at heavier dosages with a low tolerance. The sensation itself can be described as powerful and overwhelming feeling of emotional bliss, contentment, and happiness.
• Anxiety suppression
• Compulsive redosing - Due to the short duration of this substance, and the addictive properties of opioids in general, there is a strong risk of compulsive redosing which is considerably dangerous considering it is very corrosive to mucous membranes.

After effects

Unlike most other opioids, the effects which occur during the offset of this compound generally feel negative and uncomfortable in comparison to the effects which occurred during its peak. This is often referred to as a "comedown" or "crash". Its effects commonly include:

• Cognitive fatigue
• Thought deceleration
• Anxiety
• Depression
• Irritability

Toxicity and harm potential

Main article: Research chemicals § Toxicity and harm potential

U-47700 has a high toxicity relative to its dose due to its extreme potency. As with all opioids, long-term effects can vary but can include diminished libido, apathy and memory loss. It is also [[Toxicity::potentially lethal when mixed with depressants like alcohol or benzodiazepines]].

It is worth noting that U-47700 crystals are particularly corrosive and somewhat caustic to mucous membranes. Careless use may deteriorate the chosen routes of administration so it is important to practice routine maintenance such as soaking the sinus cavity with water prior to and following insufflation. It is unwise to vaporise the substance as it can damage the lungs. Sublingual administration is likely to damage the skin in the mouth.

Combined consumption of U-47700 and fentanyl caused one fatality in Belgium. At least 17 opioid overdoses and several deaths in the USA have also been connected with the use of U-47700.

It is strongly recommended that one use harm reduction practices, and take extreme caution when using this substance.

Tolerance and addiction potential

As with other opioids, the chronic use of U-47700 can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal symptoms may occur if a person suddenly stops their usage.

Tolerance to many of the effects of U-47700 develops with prolonged and repeated use. The rate at which this occurs develops at different rates for different effects, with tolerance to the constipation-inducing effects developing particularly slowly for instance. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). U-47700 presents cross-tolerance with [[Cross-tolerance::all other opioids]], meaning that after the consumption of U-47700 all opioids will have a reduced effect.

Dangerous interactions

Although many drugs are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

• Depressants (1,4-Butanediol, 2m2b, alcohol, barbiturates, benzodiazepines, GHB/GBL, methaqualone) - This combination can result in dangerous or even fatal levels of respiratory depression. These substances potentiate the muscle relaxation, sedation and amnesia caused by one another and can lead to unexpected loss of consciousness at high doses. There is also an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
• Dissociatives - This combination can result in an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
• Stimulants - It is dangerous to combine U-47700, a depressant, with stimulants due to the risk of excessive intoxication. Stimulants decrease the sedative effect of U-47700, which is the main factor most people consider when determining their level of intoxication. Once the stimulant wears off, the effects of U-47700 will be significantly increased, leading to intensified disinhibition as well as other effects. If combined, one should strictly limit themselves to only taking a certain amount of U-47700.

Legal issues

This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it.

• Sweden - Following its sale as a designer drug, U-47700 was made illegal in Sweden on 26 January 2016.
• Finland - U-47700 is an Annex 1 drug in Finland, making its sale, production and importation illegal.
• United Kingdom - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
• United States - While U-47700 is not scheduled on a federal level, the State of Ohio recently made U-47700 a Schedule I drug. This is not a federal or nationwide action and can only be enforced in the State of Ohio. On September 7th, 2016, the DEA Office of Diversion Control announced that they intend to temporarily schedule U-47700 as a Schedule I drug.

See also

• Responsible use
• Depressants
• Opioid

External links

• U-47700 (Wikipedia)
• U-47700 (Erowid)
• U-47700 (Bluelight)
• U-47700 (Reddit)
• U-47700 (TripSit Factsheets)